Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126699943 | 12669994 | 3 | F | 20160913 | 20160821 | 20160919 | PER | PHEH2016US020682 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160919 | CN | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126699943 | 12669994 | 1 | PS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.0625 MG (0.25 ML), QOD (WEEK 1-2) | 54223-1A | 125290 | .25 | ML | SOLUTION FOR INJECTION | ||||||
| 126699943 | 12669994 | 2 | SS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.125 MG (0.5 ML), QOD (WEEK 3-4) | 54223-1A | 125290 | .5 | ML | SOLUTION FOR INJECTION | ||||||
| 126699943 | 12669994 | 3 | SS | EXTAVIA | INTERFERON BETA-1B | 1 | Subcutaneous | 0.1875 MG (0.75 ML), QOD (WEEK 5-6) | 54223-1A | 125290 | .75 | ML | SOLUTION FOR INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126699943 | 12669994 | 1 | Multiple sclerosis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126699943 | 12669994 | Arthralgia | |
| 126699943 | 12669994 | Burning sensation | |
| 126699943 | 12669994 | Chills | |
| 126699943 | 12669994 | Injection site bruising | |
| 126699943 | 12669994 | Injection site haemorrhage | |
| 126699943 | 12669994 | Injection site mass | |
| 126699943 | 12669994 | Injection site pain | |
| 126699943 | 12669994 | Injection site rash | |
| 126699943 | 12669994 | Musculoskeletal pain | |
| 126699943 | 12669994 | Nausea | |
| 126699943 | 12669994 | Product quality issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |